2020-02-12T13:30:15-06:00 2019-06-30 KPMG LLP 345 PARK AVE NEW YORK NY 10154 990 2018-07-01 231907729 JDRF INTERNATIONAL % EMMA PANGILINAN-ROSALES JDRF 2127859500 200 VESEY STREET 28TH FLOOR NEW YORK NY 10281 JOANNE MARTZ CFO 2020-02-11 true DEVIN DUNCAN P01249521 2127859700 167.68.102.5 20543020200435000000 2020-02-12 P E665B3E7A8D0C3A51E67724EBAB5121B0EE8EB14 B09A8F7452AAEB109EF01FBCB66ABFE0CB6B8889 2018 2020-09-23 17:36:50Z X AARON KOWALSKI 200 VESEY STREET 28TH FLOOR NEW YORK NY 10281 306560671 false X www.jdrf.org X 1970 PA Improving lives today and tomorrow by accelerating life-changing breakthroughs to cure, prevent and treat T1D and its complications. SEE SCHEDULE O 35 35 881 235000 225709 186965 219968105 215659011 0 0 7177001 19973309 2970878 3697145 230115984 239329465 84651980 89137491 0 0 81433187 80309185 2328 339984 31501935 42340180 42783392 208427675 212570052 21688309 26759413 226353181 244434766 129947696 128633286 96405485 115801480 X AT JDRF, WE WORK TIRELESSLY TO ACCELERATE BREAKTHROUGHS TO CURE, PREVENT AND TREAT TYPE 1 DIABETES (T1D). WE CONTINUALLY EXPAND OUR SCIENTIFIC KNOWLEDGE, OUR CONNECTIONS AND COLLABORATIONS, OUR PARTNERS AND GLOBAL PRESENCE TO UNLOCK THE SCIENCE THAT WILL STOP T1D. WHILE WE FIGHT FOR A CURE, WE STRIVE JUST AS HARD TO DEVELOP THERAPIES TO HELP PEOPLE RIGHT NOW. JDRF AND OUR SCIENTISTS ARE LEADING T1D RESEARCH AROUND THE WORLD. WE ADDRESS KEY GAPS TO MOVE RESEARCH FASTER AND FARTHER ACROSS THE DEVELOPMENT PIPELINE AND TO TRANSLATE BREAKTHROUGHS INTO NEW THERAPIES FOR PEOPLE WITH T1D. THIS ENABLES US TO ADVANCE SCIENCE WITH THE MOST POTENTIAL AND TO DRIVE RESEARCH THAT ATTRACTS MORE RESOURCES AND SCIENTIFIC EXPERTISE TO THE FIELD. WE INVEST IN THE EARLY STAGES, ALLOWING RESEARCHERS TO PURSUE INNOVATIVE IDEAS AND APPROACHES THAT WILL LEAD TO BREAKTHROUGH TREATMENTS. JDRF ALSO WORKS TO DRIVE NEW THERAPIES AND TECHNOLOGIES TO MARKET SO THEY GET INTO THE HANDS OF PEOPLE WITH T1D MORE QUICKLY. false false 89137491 89137491 RESEARCH FUNDING - FOR THE FY19 PERIOD ENDING JUNE 30, 2019, JDRF DIRECTLY FUNDED RESEARCH GRANTS AND INDUSTRY AGREEMENTS FOR WHICH $89 MILLION IN RESEARCH GRANT EXPENSE, NET WAS RECOGNIZED ACCORDING TO GAAP AND EXCLUDING $21 MILLION OF PROGRAMMATIC RESEARCH INVESTMENTS WHICH ARE RECORDED TO THE ORGANIZATION'S BALANCE SHEET. FOR AN EXPANDED DESCRIPTION OF PROGRAM SERVICE ACTIVITIES RELATED TO DIRECT RESEARCH FUNDING, SEE SCHEDULE O. 16986262 RESEARCH SUPPORT - JDRF MAINTAINS AN IN-HOUSE TEAM OF SKILLED SCIENTIFIC, MEDICAL, POLICY AND GOVERNMENT RELATIONS PROFESSIONALS WHO PLAY A CRITICAL ROLE IN LEADING AND SUPPORTING THE EVALUATION OF RESEARCH FUNDING OPPORTUNITIES BY JDRF AND INFLUENCING RESEARCH DIRECTION AND THE DISBURSEMENT OF RESEARCH FUNDS FROM OTHERS. THESE PROFESSIONALS ALSO WORK WITH REGULATORY AND POLICY OFFICIALS TO ENSURE THAT RESEARCH CAN PROCEED WITHOUT DELAY AND RESULTS ARE UNDERSTOOD BY HEALTHCARE DECISION MAKERS.FOR AN EXPANDED DESCRIPTION OF PROGRAM SERVICE ACTIVITIES RELATED TO RESEARCH SUPPORT, SEE SCHEDULE O. 53426056 PUBLIC EDUCATION AND OUTREACH - JDRF EDUCATES THE COMMUNITY AND PROVIDES OUTREACH SERVICES TO NEWLY DIAGNOSED CHILDREN AND ADULTS, THEIR FAMILIES AND OTHERS ABOUT T1D AND ITS COMPLICATIONS.FOR AN EXPANDED DESCRIPTION OF PROGRAM SERVICE ACTIVITIES RELATED TO PUBLIC EDUCATION AND OUTREACH, SEE SCHEDULE O. 159549809 true false false true false false false false false true true false true false true true false true false true true true false true true true false true false true false false false false false false false false true false false false true true true false false false true 951 6 true 881 true true true true IS NL false false false true true false false false true false false false X 35 35 false false false false false false false true true false true true true true true true true true true true true true AL AK AZ AR CA CO CT DE DC FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY X X EMMA PANGILINAN-ROSALES 2124797550 200 VESEY STREET 28TH FLOOR NEW YORK NY 10281 X JEFF ADAMS FY19-21 BOARD MEMBER 3.0 0.0 X 0 0 0 MICHAEL ALTER FY19-21 BOARD MEMBER 3.0 0.0 X 0 0 0 BRANDON ARBITER FY18-20 BOARD MEMBER 3.0 0.0 X 0 0 0 NANETTE DETURK FY17-19 CHAIR, ADVOCACY 5.0 0.0 X 0 0 0 MICHELLE GRIFFIN FY17-19 CHAIR, DEVELOPMENT 5.0 0.0 X 0 0 0 STEPHEN NEWMAN MD FY17-19 BOARD MEMBER 3.0 0.0 X 0 0 0 RANDY ANDERSON FY18-20 BOARD MEMBER 3.0 0.0 X 0 0 0 TIMOTHY CLARK FY18-20 BOARD MEMBER 3.0 0.0 X 0 0 0 MARY ELIZABETH BUNZEL FY18-19 CHAIR, CHANCELLORS 5.0 0.0 X X 0 0 0 LISA REED FY18-20 BOARD MEMBER 3.0 0.0 X 0 0 0 MARVIN DAITCH FY19-21 BOARD MEMBER 3.0 0.0 X 0 0 0 MIKE NORONA FY19-21 BOARD MEMBER 3.0 0.0 X 0 0 0 MARGERY PERRY FY19-21 CHAIR, RESEARCH 5.0 0.0 X 0 0 0 LISA WALLACK FY19-21 CHAIR, NOMINATING 5.0 0.0 X X 0 0 0 SEAN DOHERTY FY17-19 CHAIR, JDRF T1D FUND LLC 5.0 0.0 X 0 0 0 PAUL HEATH FY17-19 BOARD MEMBER 3.0 0.0 X 0 0 0 KAREN JORDAN FY19-21 BOARD MEMBER 3.0 0.0 X 0 0 0 JOHN KAMPFE FY17-19 BOARD MEMBER 3.0 0.0 X 0 0 0 JEFF PLUMER FY19-21 BOARD VICE-CHAIR 10.0 0.0 X X 0 0 0 DOUG LOWENSTEIN FY19-21 BOARD MEMBER 3.0 0.0 X 0 0 0 DAYTON OGDEN FY17-19 BOARD MEMBER 3.0 0.0 X 0 0 0 ANGIE PLATT FY17-19 BOARD MEMBER 3.0 0.0 X 0 0 0 JERRY WISLER FY17-19 BOARD MEMBER 3.0 0.0 X 0 0 0 KAREY L WITTY FY17-19 CHAIR, AUDIT 5.0 0.0 X 0 0 0 GRANT BEARD FY18-20 CHAIR, FINANCE 5.0 0.0 X X 0 0 0 STEVEN DAVIS FY18-20 BOARD MEMBER 3.0 0.0 X 0 0 0 CATHY BAIER FY18-20 BOARD MEMBER 3.0 0.0 X 0 0 0 JENNIFER BENNETT FY18-20 BOARD MEMBER 3.0 0.0 X 0 0 0 JOE LACHER FY18-20 CHAIR, TALENT & COMPENSATION 5.0 0.0 X 0 0 0 KIM ROOSEVELT FY18-20 BOARD MEMBER 5.0 0.0 X 0 0 0 JENNIFER SCHNEIDER FY19-21 BOARD MEMBER 3.0 0.0 X 0 0 0 MATT VAREY FY18-20 BOARD MEMBER 3.0 0.0 X 0 0 0 ELLEN LEAKE FY17-19 CHAIRMAN OF THE BOARD 20.0 0.0 X X 0 0 0 MICHAEL SOPER FY19-21 BOARD MEMBER 3.0 0.0 X 0 0 0 CHRISTOPHER TURNER FY18-20 CHAIR, INVESTMENTS 5.0 0.0 X 0 0 0 DEREK RAPP PRESIDENT AND CEO 50.0 0.0 X 800000 0 49089 SANDRA HIJIKATA CHIEF DEV OFFICER & ASST. SECY 50.0 0.0 X 443750 0 21194 JILL CLARK CHIEF OF STAFF & ASST. SECY 50.0 0.0 X 353603 0 19251 JOANNE MARTZ BEGAN 1018 CFO 50.0 0.0 X 79982 0 1371 JONATHAN R BEHR MANAGING DIRECTOR JDRF-T1D FND 50.0 0.0 X 499333 0 51654 AARON KOWALSKI CHIEF MISSION OFFICER 50.0 0.0 X 502667 0 48716 ALISA NORRIS CHIEF MARKETING OFFICER 50.0 0.0 X 403200 0 53539 JULIA GREENSTEIN VP RESEARCH 50.0 0.0 X 319567 0 14996 SUSAN YUN CHIEF PEOPLE OFFICER 50.0 0.0 X 353333 0 18647 CYNTHIA RICE SVP ADVOCACY AND POLICY 50.0 0.0 X 342405 0 49089 MARK GREENE THRU 518 FORMER CFO & ASST. TRES 0.0 0.0 X 351877 0 4694 4449717 0 332240 167 true true false 10UP LLC 2765 CARRADALE DR ROSEVILLE CA 95661 WEB DEVELOPMENT 422794 CDS GLOBAL 1901 BELL AVE DES MOINES IA 50315 3RD PARTY LOCK BOX 386914 BLUE STATE DIGITAL 101 AVE OF THE AMERICAS NEW YORK NY 10013 DIGITAL CONSULTING 1918746 AKA ENTERPRISE SOLUTIONS 875 SIXTH AVE 20th FLOOR NEW YORK NY 10001 EPM IMPLEMENTATION 891856 CONNECTIONS MEDIA LLC 1728 14th St NW 4309 WASHINGTON DC 20009 MARKETING CONSULTING 319725 23 4178999 130162354 81317658 21299838 215659011 0 2663884 225709 2438175 0 0 0 0 0 53440349 36130924 17309425 17309425 17309425 31012479 130162354 31012479 1471466 87803 1383663 1383663 0 0 0 MISC REVENUE 900099 2313482 2313482 2313482 239329465 225709 23444745 58486700 58486700 0 30650791 30650791 0 2675800 1605480 374612 695708 0 61896753 35871461 10947789 15077503 1673604 962879 291070 419655 9489943 5379325 1630105 2480513 4573085 2583998 851259 1137828 3314924 2343258 396780 574886 624888 382742 174440 67706 235095 95 235000 649491 649491 339984 339984 216069 216069 2766436 1749921 355780 660735 4963685 2714384 312422 1936879 1954418 873263 332251 748904 5710525 2395705 1552447 1762373 0 7088084 3936420 1208905 1942759 3036195 1415332 831452 789411 0 1394302 837454 194329 362519 0 0 3872196 1357225 836085 1678886 513638 312292 88859 112487 OUTREACH EXPENSES 3629031 3285588 251150 92293 DUES & FEES 1518853 887209 265562 366082 OTHER MISC EXPENSES 1295562 868796 171942 254824 212570052 159549809 21518308 31501935 X 2052275 525773 0 1526502 X 14717083 19125818 39185381 36566833 29143990 30267097 21529716 20525959 0 0 0 0 1500000 6720000 0 0 5991334 6103129 28323770 22428738 7329209 5895032 65033089 93573878 30662349 4213073 11261030 21443947 0 0 0 0 226353181 244434766 22350808 16774462 94919621 100065608 10051979 9232753 0 0 0 0 0 0 0 0 0 0 2625288 2560463 129947696 128633286 X 57009483 76838325 31828002 31075322 7568000 7887833 96405485 115801480 226353181 244434766 26759413 -7363418 X false true X true false X 198918214 196804267 199896852 219968105 215659011 1031246449 0 0 198918214 196804267 199896852 219968105 215659011 1031246449 2167760 1029078689 987577 465379 548825 1309523 2439225 5750529 2516 112437 33150 138747 186965 473815 256146 94769 283014 1793044 2313482 4740455 1042211248 0.98740 0.98519 X false true true false true 11027 true 73148 true 5945 true 663113 true 121407 false 874640 false JDRF LOBBYING ACTIVITIES FORM 990- SCH-C- GENERAL STATEMENT OF ACTIVITIES JDRF is the leading global organization funding type 1 diabetes (T1D) research, focused on curing T1D and improving lives. JDRF's advocacy includes lobbying activity to ensure Congress continues to invest in critically important medical research and puts in place policies to advance development and access to therapies to cure T1D and help people stay as healthy as possible until that day. JDRF has been instrumental in securing the renewal of the Special Diabetes Program, which provides $150MM annually for T1D research at the National Institutes of Health. JDRF staff and volunteers communicate with government officials through email, phone calls, and meetings, to educate them on issues and encourage the advancement of legislation. 7567601 221441 102034 3243 7887833 7341367 268304 42070 7567601 7176427 367446 202506 7341367 7141514 37913 3000 7176427 7426222 11292 296000 7141514 1.00000 false false 4935841 4437766 498075 23387929 17990972 5396957 5895032 T1D FUND PROGRAM RELATED INVES 21443947 F 21443947 0 SPLIT INTEREST CHRT RMDR TRUST 2560463 2560463 X 231749978 -7363418 -216069 -7579487 239329465 239329465 212353983 212353983 216069 216069 212570052 ORGANIZATION'S ENDOWMENT FUNDS FORM 990, PART X, LINE 28 & 29 & SCH D, PART V THE ORGANIZATION UTILIZES EARNINGS ON ENDOWMENT FUNDS IN THE MANNER SPECIFIED BY THE DONOR AND/OR FOR SUPPORTING THE ORGANIZATIONS GENERAL EXEMPT PURPOSE. UNCERTAIN TAX POSITIONS 990 SCH-D, PART X, LINE 2 JDRF IS A NOT FOR PROFIT ORGANIZATION EXEMPT FROM FEDERAL INCOME TAXES UNDER SECTION 501 (C) (3) OF THE INTERNAL REVENUE CODE AND IS ORGANIZED UNDER THE LAWS OF THE COMMONWEALTH OF PENNSYLVANIA. THE EFFECT OF INCOME INCOME TAX POSITIONS IS RECOGNIZED ONLY IF THE POSITIONS ARE MORE LIKELY THAN NOT OF BEING SUSTAINED. INCOME GENERATED FROM ACTIVITIES UNRELATED TO JDRF'S EXEMPT PURPOSE IS SUBJECT TO TAX UNDER INTERNAL REVENUE CODE SECTION 511. UNRELATED BUSINESS INCOME TAX LIABILITY WAS INSIGNIFICANT FOR THE YEARS ENDING JUNE 30, 2019 AND 2018. true North America Grantmaking RESEARCH GRANTS 4958404 Europe (Including Iceland and Greenland) Grantmaking RESEARCH GRANTS 17529266 Middle East and North Africa Grantmaking RESEARCH GRANTS 890206 East Asia and the Pacific Grantmaking RESEARCH GRANTS 7272915 Europe (Including Iceland and Greenland) 2 2 Program Services RESEARCH SUPPORT 532586 Central America and the Caribbean Investments INVESTMENTS 33187 2 2 2 2 31216564 31216564 Europe (Including Iceland and Greenland) IMMUNE THERAPIES 40000 CHECK/WIRE N/A N/A East Asia and the Pacific 120917 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) IMMUNE THERAPIES 225155 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 1282048 CHECK/WIRE N/A N/A Middle East and North Africa 319706 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 899045 CHECK/WIRE N/A N/A East Asia and the Pacific 579500 CHECK/WIRE N/A N/A East Asia and the Pacific 150000 CHECK/WIRE N/A N/A North America IMMUNE THERAPIES 58716 CHECK/WIRE N/A N/A East Asia and the Pacific 200000 CHECK/WIRE N/A N/A North America 1082089 CHECK/WIRE N/A N/A North America 1442432 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) IMMUNE THERAPIES 599813 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 385109 CHECK/WIRE N/A N/A North America 220285 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 150000 CHECK/WIRE N/A N/A East Asia and the Pacific 360000 CHECK/WIRE N/A N/A North America IMMUNE THERAPIES 249714 CHECK/WIRE N/A N/A North America IMMUNE THERAPIES 435597 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) IMMUNE THERAPIES 247317 CHECK/WIRE N/A N/A East Asia and the Pacific 975505 CHECK/WIRE N/A N/A North America 66900 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) IMMUNE THERAPIES 1342769 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) IMMUNE THERAPIES 313508 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 678455 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 249976 CHECK/WIRE N/A N/A North America 341953 CHECK/WIRE N/A N/A East Asia and the Pacific ARTIFICIAL PANCREAS 250000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 185500 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 1191662 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) IMMUNE THEPAPIES 346739 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 350000 CHECK/WIRE N/A N/A Middle East and North Africa IMMUNE THERAPIES 34985 CHECK/WIRE N/A N/A Middle East and North Africa IMMUNE THERAPIES 150335 CHECK/WIRE N/A N/A East Asia and the Pacific 250000 CHECK/WIRE N/A N/A North America IMMUNE THERAPIES 400000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 1401418 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) BETA CELL 125000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) IMMUNE THERAPIES 266343 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) IMMUNE THERAPIES 118496 CHECK/WIRE N/A N/A East Asia and the Pacific IMMUNE THERAPIES 618750 CHECK/WIRE N/A N/A East Asia and the Pacific IMMUNE THERAPIES 938315 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) IMMUNE THERAPIES 72589 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) BETA CELL 225000 CHECK/WIRE N/A N/A East Asia and the Pacific IMMUNE THERAPIES 710572 CHECK/WIRE N/A N/A North America IMMUNE THERAPIES 429400 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) IMMUNE THERAPIES 406488 CHECK/WIRE N/A N/A East Asia and the Pacific IMMUNE THERAPIES 249466 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) IMMUNE THERAPIES 83325 CHECK/WIRE N/A N/A East Asia and the Pacific IMMUNE THERAPIES 450000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) IMMUNE THERAPIES 350000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) IMMUNE THERAPIES 410738 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) IMMUNE THERAPIES 349560 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) IMMUNE THERAPIES 109771 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) IMMUNE THERAPIES 92273 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) IMMUNE THERAPIES 346832 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) IMMUNE THERAPIES 174790 CHECK/WIRE N/A N/A North America 250000 CHECK/WIRE N/A N/A East Asia and the Pacific 600000 CHECK/WIRE N/A N/A East Asia and the Pacific 109945 CHECK/WIRE N/A N/A East Asia and the Pacific 109945 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 1025000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 104413 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 374799 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 197964 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 300000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 259735 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 199928 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 130000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 95000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 350000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 563368 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 143920 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) ARTIFICIAL PANCREAS 50000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 641505 CHECK/WIRE N/A N/A East Asia and the Pacific 600000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) BETA CELL 250000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 248724 CHECK/WIRE N/A N/A Middle East and North Africa 385180 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) BETA CELL 190017 CHECK/WIRE N/A N/A 61 19 true false true true false false GRANT MONITORING PROCEDURES SCH-F PART I LINE 2 Research grants are awarded by JDRF with the support of JDRF's Research Committee comprised of "JDRF Board members and other volunteers" following the recommendations of an in-house team of professional scientific staff and with input from external scientific reviewers and patient advocates. The review process includes the following criteria: (1) The scientific merit of the proposed research outlined in a grant application and (2) The relationship of the proposed research to JDRF's goal to cure, prevent and treat T1D and its complications. The scientific research team and grant administration staff maintain close contact with grantees, providing advice and evaluation, reviewing progress reports, reviewing research expenditures versus agreed budgets, and helping disseminate research results. X X X X X true INSURANCE AUTO AUCTIONS LLC TWO WESTBROOK CORORATE CENTER SUIT WESTCHESTER IL 60154 CAR DONATION true 261400 107183 154217 261400 107183 154217 AL AK AZ AR CA CO CT DE DC FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY ILLINOIS GALA 5758207 4870051 888156 39988 342765 374444 130959 NORTHWEST GALA 3352228 2408464 943764 22224 300930 11919 426882 181809 370 152064398 122883839 29180559 28565 3591507 3764670 5535817 16260000 161174833 130162354 31012479 50789 3932425 4119354 6337143 16572768 31012479 1471255 59238 28565 false 1471255 59238 28565 87803 1383452 AL AK AZ AR CA CO CT DE DC FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY true false false false 1.00000 JIMMY CHAN 26 BROADWAY-14TH FLOOR NEW YORK NY 10004 false JIMMY CHAN SR ACCCOUNTANT -JDRF 0 FILING GAMING APPLICATIONS AND REPORTS X false SCHEDULE G, PART I, LINE 2 INSURANCE AUTO AUCTIONS LLC IS A STATE LICENSED PROFESSIONAL FUNDRAISER THAT HANDLES ALL ASPECTS OF CARS BEING DONATED TO JDRF. DONORS CONTACT THE COMPANY DIRECTLY THROUGH A TOLL FREE NUMBER TO COORDINATE THE DONATION, FOLLOWING WHICH INSURANCE AUTO AUCTIONS HANDLES ALL REQUIRED IRS 1098C REPORTING. FOR THE PERIOD ENDING 6/30/19, THE CAR PROGRAM RAISED $261,400 WITH TOTAL EXPENSES OF $107,183 WITH THE NET PROCEEDS OF $154,217 PROVIDED DIRECTLY TO JDRF. JDRF PAYS NO ADDITIONAL EXPENSES OR FEES TO INSURANCE AUTO AUCTIONS FOR THIS PROGRAM. true BENAROYA RESEARCH INST AT VIRGINIA MASON 1201 9TH AVE SEATTLE WA 98101 910653422 501(C)3 1960925 N/A N/A ANN AND ROBERT LURIE CHILDREN'S HOSPITAL 225 EAST CHICAGO AVENUE CHICAGO IL 60611 362170833 501(C)3 60000 N/A N/A IMMUNE THERAPIES CAPILLARY BIOMEDICAL INC 56 HAVENWOOD IRVINE CA 92617 464787731 590000 N/A N/A IMMUNE THERAPIES CORNELL UNIVERSITY 377 PINE TREE RD ITHACA NY 14850 150532082 501(C)3 131887 N/A N/A IMMUNE THERAPIES CAM MED LLC 29 EXETER STREET WEST NEWTON MA 02465 999999999 686927 N/A N/A IMMUNE THERAPIES UNIVERSITY OF ARIZONA PO BOX 210158 TUCSON AZ 85004 113661893 501(C)3 599963 N/A N/A CRITICAL PATH INSTITUTE 1730 EAST RIVER ROAD TUCSON AZ 85718 201991334 501(C)3 228000 N/A N/A INDIANA UNIVERSITY 980 INDIANA AVENUE INDIANAPOLIS IN 46202 356018940 501(C)3 1217159 N/A N/A BETH ISRAEL MEDICAL CENTER 330 BROOKLINE AVE BOSTON MA 02215 135564934 501(C)3 570000 N/A N/A JOSLIN DIABETES CENTER 1 JOSLIN PL BOSTON MA 02215 042203836 501(C)3 3172354 N/A N/A FREQUENCY THERAPEUTICS 300 TECHNOLOGY SQUARE WOBURN MA 01801 999999999 122415 N/A N/A MASSACHUSETTS INSTITUTE OF TECHNOLOGY 77 MASSACHUSETTS AVE CAMBRIDGE MA 02139 042103594 501(C)3 879914 N/A N/A INDIANA BIOSCIENCES RES INST 1345 W 16TH STREET INDIANAPOLIS IN 46202 462882271 501(C)3 150000 N/A N/A MAYO CLINIC 1216 2ND ST SW ROCHESTER MN 55902 411405254 501(C)3 186794 N/A N/A IMMUNE THERAPIES GEORGIA TECH RESEARCH CORP 505 TENTH STREET ATLANTA GA 30332 580603146 501(C)3 358716 N/A N/A IMMUNE THERAPIES STANFORD UNIVERSITY 291 CAMPUS DRIVE STANFORD CA 94305 941156365 501(C)3 962302 N/A N/A HEALTH PARTNERS INSTITUTE PO BOX 1524 MINNEAPOLIS MN 55440 999999999 261319 N/A N/A RTI INTERNATIONAL RES TRIANGLE PK RES TRIANGLE NC 27709 440680117 501(C)3 66700 N/A N/A OREGON HEALTH & SCIENCE UNIVERSITY 3181 SW SAM JACKSON PORTLAND OR 97239 237083114 501(C)3 358472 N/A N/A IMMUNE THERAPIES IBM 1 N CASTLE DR ARMONK NY 10504 999999999 1465000 N/A N/A IMMUNE THERAPIES PACIFIC DIABETES TECHNOLOGIES 12154 SW GARDEN PLACE PORTLAND OR 97223 999999999 501(C)3 147126 N/A N/A UNIVERSITY OF FLORIDA 1600 SW ARCHER ROAD GAINESVILLE FL 32610 590974739 501(C)3 1659166 N/A N/A UNIVERSITY OF VIRGINIA 104 MIDMONT LN CHARLOTTESVILLE VA 22902 416042488 501(C)3 656087 N/A N/A UNIVERSITY OF MICHIGAN 2003 S STATE STREET ANN ARBOR MI 48109 386006309 501(C)3 1129564 N/A N/A LOCKHEED MARTIN 199 BORTON LANDING RD MOORESTOWN NJ 08057 999999999 523815 N/A N/A IMMUNE THERAPIES UNIVERSITY OF CALIFORNIA 3333 CA ST SAN FRANCISCO CA 94122 956006143 501(C)3 4987186 N/A N/A UNIVERSITY OF WISCONSIN-MADISON 1220 LINDEN DRIVE MADISON WI 53706 396006492 501(C)3 499527 N/A N/A UT SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BLVD DALLAS TX 75390 756002868 501(C)3 903171 N/A N/A VANDERBILT UNIVERSITY MEDICAL CENTER 1211 MEDICAL CENTER DR NASHVILLE TN 37232 620476822 501(C)3 866610 N/A N/A LOUISIANA STATE UNIV HEALTH SCIENCE 433 BOLIVAR STREET NEW ORLEANS LA 70112 270158443 501(C)3 125000 N/A N/A IMMUNE THERAPIES BAYLOR COLLEGE OF MEDICINE-RESEARCH INSTITUTE ONE BAYLOR PLAZA HOUSTON TX 77030 751921898 501(C)3 250000 N/A N/A BROAD INSTITUTE 415 MAIN STREET CAMBRIDGE MA 02142 263428781 501(C)3 250000 N/A N/A NAT INST OF DIABETES & DIGESTIVE DISEASES 6707 DEMOCRACY BLVD BETHESDA MD 20892 999999999 200000 N/A N/A JAEB CENTER FOR HEALTH RESEARCH FND 15310 Amberly Drive TAMPA FL 33647 593187624 501(C)3 2718325 N/A N/A YALE UNIVERSITY PO BOX 209010 NEW HAVEN CT 06520 060646973 501(C)3 562625 N/A N/A IMMUNE THERAPIES SFC FLUIDICS INC 534 WEST RES CENTER FAYETTEVILLE AR 72701 999999999 225000 N/A N/A IMMUNE THERAPIES UNIVERSITY OF ALABAMA AT BIRMINGHAM 1720 2ND AVS S BIRMINGHAM AL 35294 636001138 501(C)3 303695 N/A N/A MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON MA 02114 042697983 501(C)3 324670 N/A N/A ICAHN SCHOOL OF MEDICINE MOUNT SINAI 1 GUSTAVE L LEVY PLACE NEW YORK NY 10029 136171197 501(C)3 393872 N/A N/A STATE UNIVERSITY OF NY AT BUFFALO 12 CAPEN HALL BUFFALO NY 14260 141368361 501(C)3 840067 N/A N/A ILLINOIS INSTITUTE OF TECHNOLOGY 3300 SOUTH FEDERAL STREET CHICAGO IL 60616 362170136 501(C)3 220484 N/A N/A UNIVERSITY OF MINNESOTA 200 OAK ST SE MINNEAPOLIS MN 55455 416007513 501(C)3 3798470 N/A N/A JACKSON LABORATORY 600 MAIN STREET BAR HARBOR ME 04609 010211513 501(C)3 314398 N/A N/A RUTGERS THE STATE UNIVERSITY 175 UNIVERSITY AVE NEWARK NJ 07107 462354111 501(C)3 243892 N/A N/A IMMUNE THERAPIES UNIVERSITY OF WASHINGTON 4333 BROOKLYN AVE NE SEATTLE WA 98195 911486484 501(C)3 663734 N/A N/A THE MEDICAL COLLEGE OF WISCONSIN 8701 W WATERTOWN MILWAUKEE WI 53226 611730890 501(C)3 580809 N/A N/A IMMUNE THERAPIES THE BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON MA 02115 042312909 501(C)3 57984 N/A N/A COMPLICATIONS TIDEPOOL 555 BRYANT ST PALO ALTO CA 94301 462302287 3999400 N/A N/A ARTIFICIAL PANCREAS UNIVERSITY OF UTAH 201 PRESIDENTS CR SALT LAKE CITY UT 84112 876000525 501(C)3 1068613 N/A N/A GLUCOSE MODULATION PROTOMER TECHNOLOGIES 530 SOUTH LAKE AVE PASADENA CA 91101 474206994 613000 N/A N/A IMMUNE THERAPIES UNIVERSITY OF SOUTHERN CALIFORNIA 3720 S FLOWER STREET LOS ANGELES CA 90089 951642394 501(C)3 168929 N/A N/A IMMUNE THERAPIES UNIVERSITY OF COLORADO 1800 GRANT STREET DENVER CO 80203 846049811 501(C)3 4896305 N/A N/A IMMUNE THERAPIES UNIVERSITY OF ILLINOIS 1200 HARRISON CHICAGO IL 60612 376006007 501(C)3 219999 N/A N/A IMMUNE THERAPIES TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 1 COLLEGE HALL PHILADELPHIA PA 19104 231352685 501(C)3 127863 N/A N/A IMMUNE THERAPIES UNITIO INC 11 AVENUE DE LAYFETTE BOSTON MA 02111 451623549 1000000 N/A N/A IMMUNE THERAPIES UNIVERSITY OF MARYLAND BALTIMORE 620 WEST LEXINGTON ST BALTIMORE MD 21201 522004514 501(C)3 274176 N/A N/A IMMUNE THERAPIES UNIVERSITY OF TEXAS HEALTH SCIENCE 7703 FLOYD CURL DRIVE SAN ANTONIO TX 78229 741586031 501(C)3 726031 N/A N/A IMMUNE THERAPIES WASHINGTON UNIVERSITY One Brookings Drive St Louis MO 63130 430653611 501(C)3 598943 N/A N/A IMMUNE THERAPIES VTV THERAPEUTICS LLC 4170 MENDENHALL OAKS HIGH POINT NC 27265 999999999 1829999 N/A N/A IMMUNE THERAPIES BOSTON CHILDREN'S HOSPITAL 300 LONGWOOD AVENUE BOSTON MA 02115 043266103 501(C)3 1704794 N/A N/A IMMUNE THERAPIES HARVARD COLLEGE 677 HUNTINGTON AVE BOSTON MA 02115 042103580 501(C)3 471632 N/A N/A IMMUNE THERAPIES BAYLOR UNIVERSITY 1301 S UNIVERSITY PARKS DR WACO TX 76798 741159753 501(C)3 109478 N/A N/A CHILDREN'S RESEARCH INSTITUTE 801 ROEDER ROAD SUITE 500 SILVER SPRING MD 20910 521654453 501(C)3 60000 N/A N/A DUKE UNIVERSITY 2138 CAMPUS DRIVE BOX 90586 DURHAM NC 27708 560532129 501(C)3 119148 N/A N/A IVIVA MEDICAL INC 100 CUMMINGS CENTER SUITE 451C BEVERLY MA 01915 999999999 30000 N/A N/A JOHNS HOPKINS UNIVERSITY 3400 N CHARLES STREET BALTIMORE MD 21218 520595110 501(C)3 150000 N/A N/A NEW YORK MEDICAL COLLEGE 40 SUNSHINE COTTAGE RD VALHALLA NY 10595 131099420 501(C)3 110000 N/A N/A PACIFIC NORTHWEST RESEARCH INSTITUTE 720 BROADWAY SEATTLE WA 98122 910667886 501(C)3 54512 N/A N/A PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY 1 LETTERMAN DR STE D3500 SAN FRANCISCO CA 94129 473355381 501(C)3 1105190 N/A N/A PHYSIOLOGIC DEVICES INC 2232 OLD STAGECOACH TRAIL ALPINE CA 91901 999999999 425722 N/A N/A PUTNAM ASSOCIATES 501 BOYLSTON STREET BOSTON MA 02116 999999999 279000 N/A N/A QUAESTIO GLOBAL PARTNERS LLC ONE KNOLLWOOD TERRACE CHESTER NJ 07930 999999999 15000 N/A N/A RENSSELAER POLYTECHNIC INSTITUTE 110 EIGHTH STREET TROY NY 12180 141340095 501(C)3 200000 N/A N/A SINCLAIR RESEARCH CENTER LLC 562 STATE ROAD DD AUXVASSE MO 65231 999999999 139776 N/A N/A STOWERS INSTITUTE FOR MEDICAL RESEARCH 1000 EAST 50TH STREET KANSAS CITY MO 64110 202993509 501(C)3 149993 N/A N/A THE OHIO STATE UNIVERSITY 281 W LANE AVE COLUMBUS OH 43210 261416129 501(C)3 145000 N/A N/A THE SCRIPPS RESEARCH INSTITUTE 10550 NORTH TORREY PINES ROAD LA JOLLA CA 92037 330435954 501(C)3 880000 N/A N/A UNIVERSITY OF CENTRAL FLORIDA 12201 RESEARCH PARKWAY SUITE 501 ORLANDO FL 32826 592924021 501(C)3 209891 N/A N/A THE UNIVERSITY OF IOWA 5-660 BOWEN SCIENCE BUILDING DEPARTMENT OF PHYSIOLOGY BIOPHYSI IOWA CITY IA 52242 426004813 501(C)3 147465 N/A N/A THE UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER 1000 STANTON L YOUNG BLVD OKLAHOMA CITY OK 73104 731563627 501(C)3 250000 N/A N/A UNIVERSITY OF MIAMI 1320 S DIXIE HWY STE 760 CORAL GABLES FL 33146 590624458 501(C)3 1288377 N/A N/A UNIVERSITY OF NEBRASKA BOARD OF REGENTS 3835 HOLDREGE VARNER HALL LINCOLN NE 68583 470049123 501(C)3 249998 N/A N/A VANDERBILT UNIVERSITY 2301 VANDERBILT PLACE NASHVILLE TN 37240 620476822 501(C)3 260816 N/A N/A VIRGINIA COMMONWEALTH UNIVERSITY PO BOX 980568 RICHMOND VA 23298 546001758 501(C)3 110000 N/A N/A WAKE FOREST UNIVERSITY HEALTH SCIENCES 1 MEDICAL CENTER BLVD WINSTON SALEM NC 27157 223849199 501(C)3 110000 N/A N/A WAVE 80 BIOSCIENCES 999999999 20000 N/A N/A TETRAGENETICS INC 91 Mystic St Arlington MA 02474 999999999 240000 N/A N/A BETA CELL 68 19 GRANT MONITORING PROCEDURES SCH-I PART I LINE 2 Research grants are awarded by JDRF's Research Committee comprised of "JDRF Board members and other volunteers" following the recommendations of an in-house team of professional scientific staff and with input from external scientific reviewers and patient advocates. The review process includes the following criteria: (1) The scientific merit of the proposed research outlined in a grant application and (2) The relationship of the proposed research to JDRF's goal to cure, prevent and treat T1D and its complications. The scientific research team and grant administration staff maintain close contact with grantees, providing advice,evaluation, research progress reports, helping disseminate research results and reviewing research expenditures versus agreed budgets. X true false X X X X X true false false false false false false true false DEREK RAPP PRESIDENT AND CEO 550000 175000 75000 12150 36939 849089 AARON KOWALSKI CHIEF MISSION OFFICER 410667 92000 0 10297 38419 551383 SANDRA HIJIKATA CHIEF DEV OFFICER & ASST. SECY 376250 67500 12150 9044 464944 MARK GREENE THRU 518 FORMER CFO & ASST. TRES 165627 186250 4694 356571 JILL CLARK CHIEF OF STAFF & ASST. SECY 276103 77500 12150 7101 372854 JONATHAN R BEHR MANAGING DIRECTOR JDRF-T1D FND 310583 188750 12150 39504 550987 ALISA NORRIS CHIEF MARKETING OFFICER 360000 43200 12150 41389 456739 JULIA GREENSTEIN VP RESEARCH 319567 12150 2846 334563 SUSAN YUN CHIEF PEOPLE OFFICER 288333 65000 10050 8597 371980 CYNTHIA RICE SVP ADVOCACY AND POLICY 277405 65000 12150 36939 391494 HOUSING ALLOWANCE SCHEDULE J PART I, LINE 1A Derek Rapp, Pres & CEO, received a housing allowance as per the terms of his employment agreement. For the 2018 calendar year, the housing allowance provided to Derek Rapp was $75,000; such amount was treated as taxable compensation and included in his Form W-2. This amount was also reported on Schedule J, Part II, Col. (B) (III). NON-FIXED PAYMENTS FORM 990, SCHEDULE J, PART I, LINE 7 JDRF AWARDS NON-FIXED PAYMENTS SUCH AS BONUSES ON A DISCRETIONARY BASIS TIED TO THE EMPLOYEES PERFORMANCE. THE NAMES OF EMPLOYEES AND THE AMOUNTS THAT WERE PAID ARE FOUND ON SCHEDULE J, PAGE 2, PART II, COL. (B) (II). SEVERANCE PAYMENTS SCHEDULE J, PART I, LINE 4A MARK GREENE RECEIVED A SEVERANCE PAYMENT OF $186,250 WHICH IS REPORTED ON SCHEDULE J, PART II, COL. (B)(III) OTHER REPORTABLE COMPENSATION. X 2 28566 TICKET SALES X 508 8431951 NET PROCEEDS OF SALE X MISC AUCTION ITEMS DONATED 28000 12839321 FAIR MARKET VALUE 0 false true true THIRD PARTY ASSISTANCE LINE 32B INSURANCE AUTO AUCTIONS LLC IS A THIRD PARTY CAR DONATION COMPANY THAT HANDLES ALL ASPECTS OF CARS BEING DONATED TO JDRF. DONORS CALL A TOLL FREE NUMBER AND THEY ARE PUT IN CONTACT WITH A TOWING SERVICE IN THEIR AREA. AFTER THE CAR IS DONATED, INSURANCE AUTO AUCTIONS HANDLES ALL IRS 1098-C REPORTING. INSURANCE AUTO AUCTIONS IS A LICENSED PROFESSIONAL FUNDRAISER AND IS LICENSED IN THE STATES THAT REQUIRE IT TO REGISTER. FOR THE PERIOD ENDING 6/30/19, INSURANCE AUTO AUCTIONS LLC RAISED $261,400 WITH TOTAL EXPENSES OF $107,183. A NET CHECK IS PAID DIRECTLY TO JDRF. JDRF DOES NOT PAY INSURANCE AUTO AUCTIONS ANY EXPENSES OR FEES DIRECTLY. TOTAL NET REVENUE FOR FY-19 WAS $154,217. NONCASH CONTRIBUTIONS FORM 990, SCHEDULE M, PAGE 1 TYPES OF PROPERTY AND THE AMOUNTS LISTED IN PART I LINES 6, 9, and 25 ARE THE ACTUAL AMOUNT THAT DONORS HAVE DONATED FOR VEHICLES, SECURITIES, AND MISC ITEMS THAT ARE SOLD AT VARIOUS AUCTIONS & RAFFLES. NET UNRELATED BUSINESS TAXABLE INCOME FORM 990, PART I, LINE 7B INCLUDES 512(A)(7) AMOUNTS THAT ARE NOT REVENUE AND, THEREFORE, NOT REPORTED AS SUCH ON FORM 990. PUBLIC DOCUMENTS FORM 990, PAGE 6, PART VI, SECTION C, LINE 19 The organization makes its governing documents, conflict of interest policy and financial statements available to the public on its website: www.JDRF.org. The public may access copies of JDRF's W-9, annual reports, 990 tax returns, 501(c)(3) IRS letter, and audited financials, at the following link: www.jdrf.org/about/financials EXECUTIVE COMPENSATION POLICY PART VI, SECTION B, LINES 15a & 15b JDRF's Board of Directors charges a Talent and Compensation Committee to develop and recommend a compensation philosophy that applies to all employees of JDRF, including recommendations regarding the compensation and benefits of JDRF senior management for approval by the Board of Directors. The Committee works in collaboration with the President and CEO and the Chief People Officer and other senior staff personnel in the JDRF Human Resources Department to ensure that 1) the Foundation's talent strategy supports and is aligned with its overall organization strategies; 2) JDRF is in compliance with IRS guidelines for determining reasonableness in pay practices; and 3) overall compensation for JDRF's key executives is competitive and aligned with pay philosophy. To attract and retain top scientific and executive talent to advance its mission, the organization pays competitive and appropriate salaries as determined by analysis of reliable data and input from independent third-party consultants. The review of JDRF executive compensation and benefits under the procedures noted above is completed annually by an independent Compensation Committee, and the basis for their determination is documented contemporaneously in the minutes of the Committee's meetings, including most recently on June 20, 2019. FORM 990 REVIEW PROCESS SECTION B, PART VI, QUESTION 11B JDRF has a rigorous standard approach to reviewing its 990. The Organization's Accounting Manager works with its outside tax professionals to prepare the return and all supporting schedules. The draft return is reviewed by a number of individuals, including JDRF's Chief Financial Officer and AVP, FINANCE and Finance, the Chief Executive Officer, other executives, its external senior tax advisor and others as necessary to ensure accuracy. Any questions and changes with respect to the draft return are addressed. Following this process, the return is reviewed by JDRF's Audit Committee of the Board of Directors with its outside tax advisors. Once approved, the return is distributed to all members of JDRF's Board of Directors for review and comment before it is filed with the Internal Revenue Service. PART III: STATEMENT OF PROGRAM SERVICE ACCOMPLISHMENTS LINE 4A ($89,137,491) RESEARCH GRANTS JDRF has played a significant role in nearly every T1D therapeutic advance made in the last 50 years. Our funding supports more than 500 active T1D research grants in the United States and 21 other countries around the world including more than 150 grants in 2019 alone, plus 75 clinical trials. We leverage partnerships with academia, industry and clinicians to accelerate the most promising research opportunities. Our highest priority is developing cures for T1D and improving lives of those living with the disease today, including research in glucose control and prevention of T1D complications. The full impact of JDRF's research investment extends well beyond direct funding. Through advocacy and influence, JDRF drives funding from other sources into the T1D research and has helped secure passage of the Special Diabetes Program, putting more than $2.8 billion in federal funding toward T1D research over the last two decades. In addition, JDRF founded the JDRF T1D Fund (www.t1dfund.org). The wholly owned subsidiary of JDRF, the Fund is a venture philanthropy fund accelerating life-changing solutions to treat, prevent and cure T1D through catalytic commercial investments. Through its investments in partnership with private capital, including venture capital, pharma and foundations, the T1D Fund seeks to attract the private investment necessary to advance drugs, devices, diagnostics, and vaccines to help people living with T1D or at risk of developing the disease. The T1D Fund invests in opportunities that drive our mission, with an exclusive focus on the best commercial opportunities. All funds go directly to support companies developing approaches to treat, prevent and cure T1D. In accordance with GAAP, $21.4MM of the T1D Fund's total investments as of June 30, 2019 are reflected in the Balance Sheet (Part X) and not included within the organization's research-related mission expense. The foundation's diversified research portfolio includes a focus on Curing T1D and Improving Lives. Curing T1D We face two key challenges in Curing T1D. We must prevent, stop or reverse: the loss of insulin-producing beta cells, and the immune systems attack on beta cells. JDRF is accelerating our work in Curing T1D by focusing on the two areas that have advanced dramatically over the last years: Beta Cell Therapies and Immune Therapies. Beta Cell Therapies: focus on replacing insulin-producing beta cells from outside sources and on internally regenerating and protecting existing beta cells. Through donor-funded research, we now know that when someone has T1D, their own body turns on itself, attacking and destroying the beta cells that create insulin. Understanding the role of beta cells -- was a breakthrough. If we can save beta cells, we can help cure T1D. Immune Therapies: focus on ways to keep the immune system from attacking and destroying beta cells, and to prevent the onset and advancement of T1D. Research has shown that immune therapies can interact with a persons immune system, training it to combat internal battles like cancer or autoimmune diseases like rheumatoid arthritis and T1D. While T1D remains one of the only major autoimmune diseases without an effective drug therapy, we know we are getting close. Improving Lives T1D brings with it daily struggles and stress that that make the challenges of living a healthy and long life with T1D very real. JDRF fights every day to advance research and technology that can reduce the burden of living with T1D and keep people as healthy as possible until we find cures. Specifically, we are striving to improve lives by driving research and work in Glucose Control Therapies and Complications Therapies which includes psychosocial well-being. Glucose Control Therapies: focus on helping those with T1D manage glucose levels and overall metabolic balance, including improved artificial pancreas technology, developing next-generation insulins and developing new drugs that control glucose in novel ways. We know that less than 30% of people with T1D in the U.S. consistently maintain target blood-glucose control levels meaning that 70% are at risk of serious health issues. Aiming to ensure our community is healthy when cures are found, we will continue our focus on bringing new innovation to this area, including improved artificial pancreas technology, next-generation insulins and new drugs that control glucose in novel ways. Complications Therapies: focus on accelerating therapies to prevent and treat kidney and eye disease and improving psychosocial well-being. We know that more than 90% of people with T1D develop eye disease within 20 years of diagnosis and that 1 in 4 develop kidney disease. We also know that prevalence of suicide is higher among young adults with T1D. Our focus on complications will be on accelerating therapies that prevent and treat kidney and eye disease. We also are expanding our support of psychosocial wellbeing. We have been supporting research of psychosocial wellbeing for several years. Now we are increasing our support as early research has shown that the burden of living with T1D takes a toll well beyond physical complications. Research also has shown us that young adults and teens with T1D are often impacted the most, with a significantly higher suicide rate. This is alarming and is our call to step up this work to help make a positive difference. LINE 4B ($16,986,262) RESEARCH SUPPORT JDRF's in-house team of skilled and credentialed scientific, policy and government relations professionals play critical roles in leading and supporting the research strategy and distribution of research funds from JDRF - and our partner organizations toward creating a world without T1D. Our professionals identify, evaluate and influence groundbreaking research for funding and work with other foundations, governments and industry to accelerate the mission we all share. JDRF professionals work with regulatory and policy officials to ensure research can proceed without delay and that advances are well understood by healthcare decision makers. As part of these efforts, JDRF organizes and funds scientific meetings, symposia, and conferences to review research proposals, ensure that JDRF's research strategy is aligned with the needs of the T1D community, and allow JDRF to provide scientific updates on the research it manages. This effort ensures that all the research is continually shared and built upon by T1D researchers around the globe. JDRF's external Research Advisory Committee (RAC) is composed of professionals who are internationally renowned for their expertise in research as well as the care and treatment of people with T1D. The RAC advises on policies related to research philosophy and procedures. JDRF's work to bring together the best minds in the field enhances JDRF's ability to forecast future scientific direction, judge the potential effectiveness of new pathways, and identify gaps where JDRF funding can make the most impact. LINE 4C ($53,426,056) PUBLIC EDUCATION JDRF is uniquely qualified to provide public education about diabetes and its complications. JDRF's efforts impact not only the millions of people living with T1D, their families and the general public, but also those at risk for developing the disease. T1D strikes both children and adults suddenly, and the critical adjustment period following a diagnosis can be overwhelming. That's why we support families navigating this challenging time. JDRF also educates people about the warning signs of T1D, aimed at ensuring timely diagnoses and reducing the potential catastrophic consequences of undiagnosed T1D. JDRF also provides information and updates about current research directions and progress and about human clinical trials that are seeking participants (including through JDRF's Clinical Trials Connection matching tool: www.jdrf.org/research/clinical-trials). Through all of our national U.S. chapters; five international affiliates in Australia, Canada, Israel, the Netherlands and United Kingdom; the 30,000 members of our social network, TypeOneNation; and more than one million supports, JDRF fights to meet T1D community's diverse needs, connecting people with local support, expert resources, and the global effort to create a world without T1D. CONFLICT OF INTEREST POLICY FORM 990- PART VI-SECT B, LINE 12C All officers, directors, key employees, board and committee members (both chapters and international boards) are required to sign a conflict of interest policy annually and disclose any conflicts. The Office of the President and CEO manages this process, and JDRF's internal audit department annually audits to ensure compliance. If any conflict does arise, the board members with the conflicts will recuse themselves from the meeting and/or vote. NET ASSET CLASSIFICATION FORM 990, PART X, LINES 27-29: THE FASB ISSUED ACCOUNTING STANDARDS UPDATE (ASU) 2016-14 NOT-FOR-PROFIT ENTITIES (TOPIC 958), PRESENTATION OF FINANCIAL STATEMENTS OF NOT-FOR-PROFIT ENTITIES, WHICH AMONG OTHER THINGS, CHANGES HOW NOT-FOR-PROFIT ENTITIES REPORT NET ASSET CLASSES. THE SIGNIFICANT REQUIREMENTS OF ASU 2016-14 INCLUDE REDUCTION IN THE NUMBER OF NET ASSET CLASSES FROM THREE TO TWO: WITH DONOR RESTRICTIONS (FORMERLY REPORTED AS TEMPORARILY RESTRICTED NET ASSETS) AND WITHOUT DONOR RESTRICTIONS (FORMERLY REPORTED AS UNRESTRICTED NET ASSETS). THE 2018 FORM 990, PART X WAS NOT UPDATED TO REFLECT THE CHANGES IN NET ASSET CLASS TERMINOLOGY; THEREFORE, JDRF HAS REPORTED NET ASSETS WITHOUT DONOR RESTRICTION AS UNRESTRICTED NET ASSETS AND NET ASSETS WITH DONOR RESTRICTION AS TEMPORARILY RESTRICTED NET ASSETS AND PERMANENTLY RESTRICTED NET ASSETS, AS APPLICABLE. JDRF T1D FUND LLC C/O JDRF - 26 BROADWAY 14TH FLOOR NEW YORK NY 10004 274967989 FUNDR/INVEST DE 14902601 71893780 JDRF CHARITABLE REMAINDER TRUST (5) ANNUITY PA true false false false false false false false false false false false false false false false false false false SCHEDULE R, PART I, LINE (1B) THE PRIMARY ACTIVITY FOR THE JDRF T1D FUND IS FUNDRAISING AND INVESTING IN TYPE ONE DIABETES RESEARCH. PLEASE SEE DETAILED DESCRIPTION ON SCHEDULE O, PART III, LINE 4A, STATEMENT OF PROGRAM SERVICE ACCOMPLISHMENTS FOR RESEARCH GRANTS.